Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Resistance cap ⢠Momentum fading Support Level: $9.20-$9.30 Resistance Level: $10.30-$10.50 OMER remains net negative over the last month, with repeated rejection at $10.30-$10.50 and fading momentum after the latest drop, while $9.20-$9.30 is the key support to watch.
Sentiment & News
Key News Insights: ⢠EMA rejection ⢠Legal scrutiny ⢠Stock pressure Omeros was hit by a major EMA rejection of narsoplimab in Europe, triggering heavy stock pressure and a series of investor investigations that keep legal overhang high.
AI Summary
OMER's thesis has shifted from a binary narsoplimab re-rating story to a much harder test of whether YARTEMLEA's early sales can build a real commercial base fast enough to offset the EMA setback, ongoing losses, and legal overhangâuntil quarterly revenue scales and the stock reclaims resistance, the risk/reward remains fragile.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |